Haemonetics (HAE)

• Market cap: $4.48B
• 1 day: -1.69%
• 5 days: 1.93%
• 1 month: 18.66%
• 3 months: 20.58%
• 6 months: -7.53%
• Year to date: 4.79%
• 1 year: -0.10%
• 5 years: -25.94%
• 10 years: 141.14%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $47.1M | Put options by funds: $21.1M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

5% less capital invested

Capital invested by funds: $4.66B [Q2] → $4.43B (-$226M) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 111

2.68% less ownership

Funds ownership: 110.43% [Q2] → 107.74% (-2.68%) [Q3]

5% less funds holding

Funds holding: 316 [Q2] → 300 (-16) [Q3]

26% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 61

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $85 5% downside
• Avg. target: $106 19% upside
• High target: $120 34% upside

8 analyst ratings

• positive: 6 75%
• neutral: 2 25%
• negative: 0 0%

Needham Mike Matson 74% 1-year accuracy 84 / 114 met price target	26% upside $112	Buy Reiterated	15 Nov 2024
Barrington Research Michael Petusky 51% 1-year accuracy 33 / 65 met price target	21% upside $108	Outperform Maintained	8 Nov 2024
Raymond James Andrew Cooper 42% 1-year accuracy 5 / 12 met price target	35% upside $120	Strong Buy Upgraded	8 Nov 2024
Barrington Research Michael Petusky 51% 1-year accuracy 33 / 65 met price target	21% upside $108	Outperform Maintained	23 Sept 2024
CL King Kristen Stewart 100% 1-year accuracy 1 / 1 met price target	30% upside $116	Buy Initiated	13 Sept 2024